| Interferon-α Maintenance in Favorable-Risk AML | Interferon alfa-2b, Peginterferon alfa-2b | Phase 2 | Recruiting | Peking University People's Hospital | Nov 9, 2026 |
| Peg IFNα-2b Therapy for Unresectable Mid to Late Stage HBV-HCC | Interferon alfa-2b, Peginterferon alfa-2b | Not applicable | Recruiting | Jinling Hospital, China | Aug 18, 2026 |
| Standardized Documentation and Assessments for Polycythemia Vera: A Quality Improvement Initiative | Ropeginterferon alfa-2b | Not applicable | Recruiting | Massachusetts General Hospital | Jul 29, 2026 |
| A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025). | Ropeginterferon alfa-2b | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | Jul 23, 2026 |
| A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in MDS/AML With TP53 Mutations | Ropeginterferon alfa-2b | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | Jun 15, 2026 |
| Thermosensitive Gel Nasal Spray With Exosomes, Azelastine, and Interferon for Acute Phase of Chronic Sinusitis | Interferon alfa-2b | Early phase 1 | Not yet recruiting | The First Affiliated Hospital of Xinxiang Medical College | Jun 9, 2026 |
| Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer | Interferon alfa-2a | Phase 2 | Not yet recruiting | Kalinski, Pawel, MD, PhD | Jun 8, 2026 |
| A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia | Interferon alfa-2b, Peginterferon alfa-2a, Peginterferon alfa-2b, Ropeginterferon alfa-2b, Interferon alfa-2a | Phase 3 | Recruiting | Incyte Corporation | Jun 3, 2026 |
| Risk Factors for Tooth Eruption Diseases | Interferon alfa-2b | Not applicable | Not yet recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | May 14, 2026 |
| Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection | Interferon alfa-2b, Peginterferon alfa-2b | Early phase 1 | Not yet recruiting | Ningbo No.2 Hospital | Apr 28, 2026 |
| Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis | Ropeginterferon alfa-2b | Phase 1 | Recruiting | University of Utah | Apr 9, 2026 |
| Effect of Storytelling on Questionnaire Completion and Quality of Collected Data in an E-Cohort | Peginterferon alfa-2a | Not applicable | Not yet recruiting | SKEZI | Mar 16, 2026 |
| Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia | Interferon alfa-2b, Peginterferon alfa-2b, Ropeginterferon alfa-2b | Phase 2 | Not yet recruiting | Jonsson Comprehensive Cancer Center | Mar 13, 2026 |
| A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV | Interferon alfa-2b, Peginterferon alfa-2b | Not applicable | Recruiting | Duan Minghui | Mar 3, 2026 |
| Safety, Tolerability, and Preliminary Efficacy of Peginterferon α-2b in Combination With an Anti-PD-1 Antibody in Patients With Advanced or Metastatic Malignant Solid Tumors | Peginterferon alfa-2b | Not applicable | Not yet recruiting | The First Affiliated Hospital of Xiamen University | Feb 27, 2026 |
| A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B | Peginterferon alfa-2a | Phase 1 | Recruiting | IntegerBio | Feb 5, 2026 |
| DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma | Peginterferon alfa-2a | Phase 1 / Phase 2 | Recruiting | Diakonos Oncology Corporation | Dec 17, 2025 |
| Evaluation of Real-World Data on Ropeginterferon Alfa-2b in Patients With Polycythemia Vera: Insights From a Multicenter Study | Ropeginterferon alfa-2b | — | Not yet recruiting | Federico II University | Dec 15, 2025 |
| Phase I/II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase | Ropeginterferon alfa-2b | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | Dec 8, 2025 |
| Prospective Cohort Study on PEG-IFN-α-2b in Improving Clinical Cure Rate of Pediatric Patients With Chronic Hepatitis B | Peginterferon alfa-2b | Phase 4 | Not yet recruiting | Nanfang Hospital, Southern Medical University | Nov 17, 2025 |
| VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B | Peginterferon alfa-2a | Phase 2 | Active, not recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Oct 23, 2023 |
| A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) | Peginterferon alfa-2a, Interferon alfa-2a | Phase 3 | Active, not recruiting | Merck Sharp & Dohme LLC | Oct 12, 2023 |
| Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. | Peginterferon alfa-2a | Phase 3 | Recruiting | BriaCell Therapeutics Corporation | Oct 10, 2023 |
| An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden | Interferon beta-1a, Interferon beta-1b, Peginterferon beta-1a | — | Active, not recruiting | Bayer | Sep 26, 2023 |
| Nivolumab in Children and Adults With Nasopharyngeal Carcinoma | Interferon beta-1a | Phase 2 | Recruiting | German Society for Pediatric Oncology and Hematology GPOH gGmbH | Aug 31, 2023 |
| A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies | Interferon beta-1a, Peginterferon beta-1a | — | Active, not recruiting | Biogen | Jan 18, 2023 |
| Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate) | Interferon beta-1a | — | Recruiting | Biogen | Dec 20, 2022 |
| AlloHCT With PegINFa for Myelofibrosis | Peginterferon alfa-2a, Interferon alfa-2a | Phase 1 | Recruiting | University of Utah | Sep 10, 2022 |
| MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera | Interferon alfa-2a | Phase 3 | Recruiting | University of Birmingham | Oct 4, 2019 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis | Interferon beta-1a, Peginterferon beta-1a | Phase 3 | Active, not recruiting | Biogen | May 22, 2019 |
| Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS | Interferon beta-1a, Interferon beta-1b, Peginterferon beta-1a | Phase 4 | Active, not recruiting | The Cleveland Clinic | May 24, 2018 |
| Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia | Interferon beta-1a | Phase 3 | Recruiting | UMC Utrecht | Apr 13, 2016 |
| Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis | Interferon beta-1a | Phase 3 | Active, not recruiting | Novartis Pharmaceuticals | Jul 4, 2013 |